Looks like a disaster. Spend, spend, spend, no growth.
A US$63 million pipeline and just one US$130k incremental sale to an existing customer. That's a 0.2% conversion rate in 3 months. Imagine if Oracle, SAS, or another enterprise-grade provider had that conversion rate; it would be lights out for the sales team.
So, there are big doubts that the pipeline is real qualified ops. maybe "would you be interested in looking again at our solutions once we have something useful to your business?"
Oddly, the share price hasn't been seriously damaged. Anything that can help automate medical AI in the future is going to be a winner; unfortunately, this is looking like they cannot control spending and not converting.
2030 is great, but ENL looks like it cannot make it
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add ENL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.020(8.33%) |
Mkt cap ! $17.31M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 22.0¢ | $6.333K | 28.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 14.35pm 14/06/2024 (20 minute delay) ? |
| ENL (ASX) Chart |